Under construction – not a live service
Sign in
Taking people in DenmarkPhase 4

Preventing complications after high-risk pancreas surgery with a combined treatment bundle

Tests hydrocortisone, octreotide and a teres patch to prevent complications after pancreatoduodenectomy in adults.

Key facts

Who runs it
Amsterdam UMC Stichting
Where
Aarhus N and Copenhagen Oe, DenmarkSee the 2 sitesAlso in 6 other countries, 22 sites
Registry title
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
Status
Recruiting
Phase
Phase 4
People taking part
460 people, planned
Started
21 Aug 2025
Expected to end
1 May 2027
Type of study
Interventional
Record updated
17 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who will have planned surgery to remove part of the pancreas (pancreatoduodenectomy) and who have a narrow pancreatic duct.

Age
Over 18 years
Sex
All sexes
Disease stage
Planned pancreatoduodenectomy for any reason, open or minimally invasive surgery. Pancreatic duct width of 3 mm or less on a CT or MRI scan before surgery.

Main reasons for not taking part

  • Under 18 years old
  • Pregnant
  • Known allergy to hydrocortisone or octreotide
  • Fungal infection throughout the body
  • Taking CYP3A4 inhibitor or inducer drugs

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Elective pancreatoduodenectomy for any indication (both minimally invasive and open)
  • Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI
  • Age >18 years

Who cannot take part

  • Concomitant use of CYP3A4 inhibitors and inducers, (see PROTOCOL CYTOCHROME P450 DRUG INTERACTION TABLE (iu.edu))
  • Known allergy/hypersensitivity to hydrocortisone or octreotide
  • Systemic fungal infection
  • <18 years old
  • Pregnant

Where in Denmark

Also in 6 other countries, 22 sites

  • Region MidtjyllandAarhus N, DenmarkTaking people
  • RigshospitaletCopenhagen Oe, DenmarkTaking people

About the trial

What the trial wants to find out

The primary aim of the PANENCA trial is to investigate the effect of a combined treatment with hydrocortisone, octreotide, teres patch (HOP bundle) on major complications after pancreatoduodenectomy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
Plain-language title
Preventing complications after high-risk pancreas surgery with a combined treatment bundleGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
17 September 2026